Last reviewed · How we verify
NCT03362749: EAST
Eastern Ablation Registry for Solid Tumor (EAST)
trial testing RFA, MWA, cryo and IRE in Solid Tumor Including Thyroid, Bone, Liver, Pancreas in 500 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 September 2017 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- RFA, MWA, cryo and IRE
Conditions studied
- Solid Tumor Including Thyroid, Bone, Liver, Pancreas — all drugs for Solid Tumor Including Thyroid, Bone, Liver, Pancreas →
Sponsor
National Taiwan University Hospital
Who can join
18 and older, any sex, with Solid Tumor Including Thyroid, Bone, Liver, Pancreas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Local tumor ablation is among the major anti-tumor modalities worldwide. Given the number of changes that have taken place in the field of tumor ablation in the past 10 years, it is our intention to ensure that this highly utilized standardization continues to remain relevant as it unites all investigators and clinicians practicing interventional oncology by providing a common language to describe therapies and outcomes, develop studies, and communicate with other medical specialties. In an attempt to attain greater Asian-wide adoption, the investigators will initiate the registry system for local tumor ablation in Taiwan, China, Korea, Singapore, Hong Kong and Thailand.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study.
Yang PC, Chen YJ, Li XY, Hsiao CY, et al · · 2021 · cited 6× · PMID 34277454 · DOI 10.3389/fonc.2021.710536
Verify or expand the search:
- PubMed search for NCT03362749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03362749 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 14 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03362749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing